結核の管理
関係書目

↑  “Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis”. Am J Respir Crit Care Med 169 (10):  1103–09. (2004). doi:10.1164/rccm.200308-1159OC. PMID 14742301.
↑  “Pulmonary resection as an adjunct in the treatment of multiple drug-resistant tuberculosis”. Ann Thorac Surg 63 (5):  1368?72. (1997). doi:10.1016/s0003-4975(97)80353-0. PMID 9146329.
↑  “Surgery increased the chance of cure in multi-drug resistant pulmonary tuberculosis”. Eur J Cardiothorac Surg 16 (2):  187–93. (1999). doi:10.1016/S1010-7940(99)00158-X. PMID 10485419.
1 2  “Pulmonary resection for multi-drug resistant tuberculosis”. J Thorac Cardiovasc Surg 121 (3):  448–53. (2001). doi:10.1067/mtc.2001.112339. PMID 11241079.
↑  “A retrospective study for the outcome of pulmonary resection in 49 patients with multidrug-resistant tuberculosis”. Int J Tuberc Lung Dis 6 (2):  143–49. (2002). PMID 11931413.
↑  “Lung resection for multidrug-resistant tuberculosis”. Asian Cardiovasc Thorac Ann 13 (2):  172–74. (2005). doi:10.1177/021849230501300216. PMID 15905349.
↑  “Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis”. J Thorac Cardiovasc Surg 128 (4):  523–28. (2004). doi:10.1016/j.jtcvs.2004.06.012. PMID 15457152.
1 2  “Surgical treatment of multi-drug resistant pulmonary tuberculosis in 188 cases 耐多藥肺結核188例的外科治療” (Chinese). Chinese Journal of Tuberculosis and Respiratory Diseases 中華結核和呼吸雜誌 29 (8):  524–26. (2006). PMID 17074264.  オリジナルの2016-01-09時点におけるアーカイブ。. https://web.archive.org/web/20160109230152/http://cnki50.csis.com.tw/kns50/detail.aspx?QueryID=27&CurRec=9.
↑  “Lobectomy or pneumonectomy for multidrug-resistant pulmonary tuberculosis can be performed with acceptable morbidity and mortality: A seven-year review of a single institution's experience”. J Thorac Cardiovasc Surg 134 (1):  194?98. (2007). doi:10.1016/j.jtcvs.2007.03.022. PMID 17599508.
↑  “The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals”. Int J Tubercul Lung Dis 8 (3):  286–98. (2004).
↑  Onwubalili JK. (1988). “Malnutrition among tuberculosis patients in Harrow, England”. Eur J Clin Nutr. 42 (4):  363–66. PMID 3396528.
↑  “Poor Micronutrient Status of Active Pulmonary Tuberculosis Patients in Indonesia”. Journal of Nutrition 130:  2953–58. (2000). doi:10.1093/jn/130.12.2953.
↑  “Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death”. Trans R Soc Trop Med Hyg. 96 (3):  291–94. (2002). doi:10.1016/S0035-9203(02)90103-3. PMID 12174782.
↑  Baldwin M; Yori, PP; Ford, C; Moore, DA; Gilman, RH; Vidal, C; Ticona, E; Evans, CA (2004). “Tuberculosis and nutrition: disease perceptions and health seeking behavior of household contacts in the Peruvian Amazon”. Int J Tuberc Lung Dis 8 (12):  1484?91. PMC 2912521. PMID 15636496. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2912521/.
↑  Sinclair, D; Abba, K; Grobler, L; Sudarsanam, TD (9 November 2011). “Nutritional supplements for people being treated for active tuberculosis.”. The Cochrane Database of Systematic Reviews (11):  CD006086. doi:10.1002/14651858.CD006086.pub3. PMC 4981643. PMID 22071828. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4981643/.
↑  “Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis”. Int J Epidemiol 37 (1):  113?19. (2008). doi:10.1093/ije/dym247. PMID 18245055.
↑  Davies PD (1985). “A possible link between vitamin D deficiency and impaired host defence to Mycobacterium tuberculosis”. Tubercle 66 (4):  301–06. doi:10.1016/0041-3879(85)90068-6. PMID 3936248.
↑  Vieth R (2011). “Vitamin D nutrient to treat TB begs the prevention question”. Lancet 377 (9761):  189, 190. doi:10.1016/S0140-6736(10)62300-8. PMID 21215444.
1 2  “Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response”. Science 311 (5768):  1770–73. (2006). doi:10.1126/science.1123933. PMID 16497887.
↑  Finsen NR (1886). Om anvendelse i medicinen af koncentrerede kemiske lysstraaler. Copenhagen, Denmark: Gyldendalske Boghandels Forlag
↑  “Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity”. Clin Pharmacol Ther 30 (3):  363–67. (1981). doi:10.1038/clpt.1981.173. PMID 7273600.
↑  “Effect of rifampicin and isoniazid on vitamin D metabolism”. Clin Pharmacol Ther 32 (4):  525–30. (1982). doi:10.1038/clpt.1982.197. PMID 7116768.
↑  “Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis”. J R Soc Med 75 (7):  533?36. (1982). PMC 1437875. PMID 7086805. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1437875/.
↑  “Long term study of the effect of rifampicin and isoniazid on vitamin D metabolism”. Tubercle 66 (1):  49–54. (1985). doi:10.1016/0041-3879(85)90053-4. PMID 3838603.
↑  Chan TY (1996). “Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong”. Int J Clin Pharmacol Ther 34 (12):  533?34. PMID 8996847.
↑  “Tuberculosis and chronic hepatitis B virus infection in africans and variation in the vitamin D receptor gene”. J Infect Dis 179 (3):  721–24. (1998). doi:10.1086/314614. PMID 9952386.
↑  “Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study”. Lancet 355 (9204):  618–21. (2000). doi:10.1016/S0140-6736(99)02301-6. PMID 10696983.
↑  ??,?翠英,??明 (2003). “?生素D受体基因多?性与肺?核易感性的病例?照研究 (A case-control study on the vitamin D receptor gene polymorphisms and susceptibility to pulmonary tuberclosis)” (Chinese). 中?流行病学?志 (Chinese Journal of Epidemiology) 24 (5):  389–92. PMID 12820934.
↑  “High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial”. Lancet 377 (9761):  242?50. (2011). doi:10.1016/S0140-6736(10)61889-2. PMID 21215445.
↑  “Adjunctive vitamin D for treatment of active tuberculosis in India: a randomised, double-blind, placebo-controlled trial.”. Lancet Infect Dis 15:  528?34. (2015). doi:10.1016/S1473-3099(15)70053-8. PMID 25863562.
↑  “Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial”. Am J Respir Crit Care Med 179 (9):  843–50. (2009). doi:10.1164/rccm.200804-567OC. PMID 19179490.
↑  “Tuberculosis and vitamin D: what's the rest of the story?”. Lancet Infect Dis 15:  489?90. (2015). doi:10.1016/S1473-3099(15)70163-5. PMC 4696485. PMID 25863560. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4696485/.
↑  Williams, C. J. B. (1849). “Cod liver oil in phthisis”. London J Med 1:  1–18. doi:10.1136/bmj.s2-1.1.1.
↑  Spector SA (2009). “Vitamin D earns more than a passing grade”. J Infect Dis 200 (7):  1015–17. doi:10.1086/605723. PMID 19673648.
↑  “A single dose of vitamin D enhances immunity to Mycobacteria”. Am J Respir Crit Care Med 176 (2):  208?13. (2007). doi:10.1164/rccm.200701-007OC. PMID 17463418.
↑  “Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes”. Immunology 57 (1):  159–63. (1986). PMC 1453883. PMID 3002968. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1453883/.
↑  “Inhibition by 1,25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages”. Infection and Immunity 55 (12):  2945–50. (1987). PMC 260011. PMID 3119492. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC260011/.
↑  “1α,25-dihydroxyvitamin D3-induced monocyte antimycobacterial activity is regulated by phosphatidylinositol 3-kinase and mediated by the NADPH-dependent phagocyte oxidase”. J Biol Chem 276 (38):  35482–93. (2001). doi:10.1074/jbc.M102876200. PMID 11461902.
↑  “IFN-γ- and TNF-independent vitamin D-inducible human suppression of mycobacteria: The role of cathelicidin LL-37”. Journal of Immunology 178:  7190–98. (2007). doi:10.4049/jimmunol.178.11.7190.
↑  “1α,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infection”. Immunology 127 (4):  539–48. (2009). doi:10.1111/j.1365-2567.2008.03024.x. PMC 2729531. PMID 19178594. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729531/.
↑  “Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household Contacts”. Am J Respir Crit Care Med 173 (8):  922–26. (2006). doi:10.1164/rccm.200512-1953OC. PMC 2662911. PMID 16474028. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662911/.
↑  “Severe of fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis”. Clin Infect Dis 42 (3):  346–55. (2006). doi:10.1086/499244. PMID 16392079.
↑  Smieja M. J.; Marchetti C. A.; Cook D. J.; Smaill F. M. (2000). “Isoniazid for preventing tuberculosis in non-HIV infected persons”. Cochrane Database of Systematic Reviews 2:  CD001363. doi:10.1002/14651858.CD001363. PMID 10796642.
↑  “Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB”. Cochrane Database Syst Rev 7:  CD007545. (2013). doi:10.1002/14651858.CD007545.pub2. PMID 23828580.
↑  “Treatment of Latent Tuberculosis Infection: A Network Meta-analysis”. Ann. Intern. Med. 161 (6):  419?28. (August 2014). doi:10.7326/M14-1019. PMID 25111745. http://annals.org/article.aspx?articleID=1895308.
↑  “Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine Tuberculosis”. Am J Respir Crit Care Med 169 (3):  421–26. (2004). doi:10.1164/rccm.200310-1380OC. PMID 14578218.
↑  “The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis”. Am J Respir Crit Care Med 168 (11):  1342–45. (2003). doi:10.1164/rccm.200305-682OC. PMID 12917230.
↑  “Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis”. Am J Respir Crit Care Med 170 (10):  1131–34. (2004). doi:10.1164/rccm.200407-885OC. PMID 15306535.
↑  TB Alliance. “TB Alliance and Bayer launch historic global TB drug trials”. September 25, 2006時点のオリジナルよりアーカイブ。2006年10月17日閲覧。
Lienhardta C, Vernonb A, Raviglionec MC (2010). “New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes” (PDF). Current Opinion in Pulmonary Medicine 16:  186?93. http://www.stoptb.org/assets/documents/research/COPM%20paper%20April%202010.pdf.
| 表 話  歴薬理学：医薬品の分類 |
| --- | --- |
消化器/代謝（A）:  胃酸中和剤 制酸薬  H2ブロッカー  プロトンポンプ阻害薬  制吐薬  瀉下薬  止瀉薬/止痢薬  抗肥満薬  血糖降下薬  ビタミン  ミネラル 
血液、血液生成器官（B）:  抗血栓薬 抗血小板剤  抗凝固薬  血栓溶解薬  抗出血薬  血小板  凝固・線溶系  抗線維素溶解性 
循環器系（C）:  心臓療法/狭心症治療薬  強心配糖体  抗不整脈薬  昇圧薬  降圧薬 利尿薬  血管拡張薬  交感神経β受容体遮断薬  カルシウム拮抗剤  レニン・アンジオテンシン・アルドステロン系 ACE阻害薬  ARB  レニン阻害薬  脂質降下薬  スタチン  フィブラート  胆汁酸捕捉因子 
皮膚（D）:  皮膚軟化剤  瘢痕形成剤  鎮痒薬  乾癬治療薬  他の皮膚薬 
泌尿生殖器系（G）:  ホルモン避妊薬  排卵誘発治療  SERM  性ホルモン 
内分泌器（H）:  視床下部脳下垂体ホルモン  副腎皮質ホルモン  鉱質コルチコイド  糖質コルチコイド  性ホルモン  甲状腺ホルモン/抗甲状腺薬 
感染（J、P、QI）:  抗菌薬  抗生物質  抗真菌薬  抗ウイルス薬  抗寄生虫薬  抗原虫薬  駆虫薬  外部寄生虫駆除剤  静注用免疫グロブリン  ワクチン 
悪性腫瘍（L01-L02）:  抗がん剤  代謝拮抗薬  抗腫瘍性アルキル化薬  紡錘体毒  抗悪性腫瘍薬  トポイソメラーゼ阻害薬 
免疫系（L03-L04）:  免疫調節薬 免疫賦活薬  免疫抑制剤 
筋肉、骨、関節（M）:  アナボリックステロイド  抗炎症薬 (NSAIDs)  抗リウマチ  副腎皮質ホルモン  筋弛緩剤  ビスホスホネート 
脳、神経（N）:  鎮痛薬  麻酔薬(全身  局所  静脈)  食欲低下薬  ADHD治療  中毒医学  抗てんかん薬  アルツハイマー治療  抗うつ薬  片頭痛治療  抗パーキンソン病薬  抗精神病薬  抗不安薬  抑制剤  エンタクトゲン  エンセオジェン  陶酔薬  幻覚剤  サイケデリック  解離性麻酔薬  譫妄誘発薬  睡眠薬/鎮静薬  気分安定薬  神経保護  スマートドラッグ  神経毒  食欲促進  セレニック  精神刺激薬  覚醒促進物質 
呼吸器（R）:  充血除去薬  気管支拡張薬  鎮咳去痰薬  抗ヒスタミン薬 
感覚器（S）:  眼科学  耳鼻咽喉科学 
その他ATC（V）:  解毒剤  造影剤  放射性医薬品  湿潤療法